International Scholarly Research Notices / 2013 / Article / Tab 1 / Clinical Study
Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line? Table 1 Patients’ characteristics.
Characteristics FLOX arm 3-week arm
valueAge Median 56 54 .45 Range 44–69 41–68 Gender Male 16 (67%) 17 (71%) .49 Female 8 (33%) 7 (29%) .35 Disease at presentation Locally advanced 15 (63%) 14 (58%) .44 Metastatic 9 (37%) 10 (42%) .23 Site of metastases Liver 5 (21%) 6 (25%) .48 Lung 1 (4%) 1 (4%) — LN 2 (8%) 2 (8%) — Peritoneal 1 (4%) 1 (4%) — others — Previous surgery Palliative 5 (21%) 4 (17%) .3 Radical 1 (4%) 1 (4%) — None Prior chemotherapy Gemcitabine single agent 14 (58%) 16 (67%) .23 Gem + 5FU 8 (34%) 6 (25%) .17 Gem + Platinol 2 (8%) 2 (8%) — Response to prior therapy Partial response — — Stable disease 2 (8%) 3 (12.5%) .12 Progression 22 (92%) 21 (87.5%) .27 Presented symptoms Pain 8 (34%) 8 (34%) — Weight loss 20 (84%) 20 (84%) —